Filing Flows › Amphastar Pharmaceuticals (AMPH) › Q3 2026 › vs Q2 2026
Amphastar Pharmaceuticals (AMPH) Q3 2026 vs Q2 2026 (quarter over quarter)
Amphastar Pharmaceuticals's revenue rose $23.7M (+13%) from $184M in Q2 2026 to $208M in Q3 2026. Gross margin 48.0% against 50.8% (-2.8 pts).
Amphastar Pharmaceuticals, Q3 2026: revenue $208M (+8% year over year), operating margin 24.5%, net earnings $37.8M, operating cash flow $43.3M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 48.0% | 50.8% | -2.8 pts |
| Operating margin | 24.5% | 21.6% | +2.9 pts |
| Net margin | 18.2% | 16.5% | +1.7 pts |
| Free cash flow margin | 16.1% | 23.2% | -7.2 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $208M | $184M | $23.7M | +13% |
| Gross profit | $99.6M | $93.5M | $6.2M | +7% |
| Cost of revenue | $108M | $90.4M | $17.5M | +19% |
| Operating profit | $50.8M | $39.7M | $11.0M | +28% |
| Operating expenses | $48.9M | $53.7M | −$4.9M | -9% |
| Pre-tax earnings | $49.1M | $38.5M | $10.5M | +27% |
| Other expense, net | $1.7M | $1.2M | $524K | +44% |
| Research & development | $20.1M | $22.2M | −$2.1M | -9% |
| Sales & marketing | $11.9M | $13.3M | −$1.4M | -11% |
| General & admin | $16.8M | $18.2M | −$1.4M | -8% |
| Net earnings | $37.8M | $30.3M | $7.4M | +24% |
| Income tax | $11.3M | $8.2M | $3.1M | +38% |
| Depreciation & amortization | $15.6M | $14.3M | $1.3M | +9% |
| Share-based compensation | $7.0M | $7.1M | −$83K | -1% |
| Working capital & other | $17.1M | $425K | $16.6M | 40× |
| Operating cash flow | $43.3M | $51.3M | −$8.0M | -16% |
| Free cash flow (OCF − capex) | $33.4M | $42.7M | −$9.4M | -22% |
| Capital expenditures | $9.9M | $8.6M | $1.4M | +16% |
Questions
How much did Amphastar Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Amphastar Pharmaceuticals's revenue rose $23.7M (+13%) from $184M in Q2 2026 to $208M in Q3 2026. Gross margin 48.0% against 50.8% (-2.8 pts).